IL10 and myeloid sarcoma: Treatment in vitro with pharmacological activation of situin-1, resveratrol, selectively normalised exaggerated production of TNFα and LT by MS B cells, while leaving the ability of these cells to produce IL-10 ‘intact’ [68].